ResearchMoz is the one stop online destination to find and buy market research reports and Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

Friday, 26 July 2013

Terbinafine (Dermatophytic Onychomycosis) - Forecast and Market Analysis to 2022 include new market research report"Terbinafine (Dermatophytic Onychomycosis) - Forecast and Market Analysis to 2022 " to its huge collection of research reports.

GlobalData has released its new PharmaPoint Drug Evaluation report, Terbinafine (Dermatophytic Onychomycosis) Forecast and Market Analysis to 2022.Dermatophytic onychomycosis (DO) is characterized as being a fungal infection of the nail. Infection can involve the nail unit (nail matrix, nail bed, or nail plate). DO isnt considered life-threatening, however can cause patients to experience discomfort, pain, and may cause physical and occupational limitations. DO patients can be identified as having thick or brittle nails along with discoloration (white and opaque). Physicians currently use direct microscopy and fungal culture tests to ensure correct diagnosis and treatment are achieved. Risk factors such as advanced age, pre-existing diabetes, or immunocompromised systems can increase the incidence of DO in patients. Current therapies consist of generics that offer substantial efficacy but sub-par safety profiles. A new wave of therapies is expected to offer topical options for patients who are unable to withstand existing generic options. These therapies are also expected to drive an increase in total drug treatment rates in the US market.

Terbinafine was first introduced by Novartis as the branded product, Lamisil, for the treatment of onychoymycosis caused by dermatophytes. The allylamine-based antifungal treatment is currently administered as an oral therapy that and is indicated to treat both toenail and fingernail DO. Novartis Lamisil lost patent protection in 2007, and since then, generic versions of the product have been available in the US market. Terbinafine works by inhibiting the enzyme squalene epoxidase and is a fungicidal therapy, which is a marked improvement over the other therapies, such as itraconazole, which is fungistatic. This prevents the conversion of squalene to squalene epoxide in the biosynthetic pathway of ergosterol, which is an integral component of the fungal cell wall.


Overview of Dermatophytic Onychomycosis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on Terbinafine including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for Terbinafine for the US from 2012 to 2022.
Sales information covered for the US

Reasons to buy

Understand and capitalize by identifying products that are most likely to ensure a robust return
Stay ahead of the competition by understanding the changing competitive landscape for Dermatophytic Onychomycosis
Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
Make more informed business decisions from insightful and in-depth analysis of Terbinafine performance
Obtain sales forecast for Terbinafine from 2012 to 2022 in the US

For More Information Kindly Contact:


Post a Comment